| Net loss | -12.12M |
| Change in warrant value and gain from warrant exercise, net | |
| Accrued incentive plan with related parties | |
| Non-cash license revenue | 0 |
| Depreciation and amortization | 523K |
| Debt conversion costs | |
| Loss on sale and disposal of property and equipment | 3K |
| Stock-based compensation expense | 861K |
| Accounts receivable | -44K |
| Prepaid expenses and other assets | 354K |
| Accounts payable, accrued liabilities and other liabilities | -769K |
| Deferred revenue | 0 |
| Reorganization Items | |
| Net cash used in operating activities | |
| Purchase of property and equipment | -1.24M |
| Proceeds from sale of property and equipment | |
| Net cash used in investing activities | |
| Principal repayment of debtor-in-possession loan financing with related party | |
| Principal repayment of 4.50% convertible senior notes | |
| Proceeds from sale of common stock, net of issuance costs | |
| Proceeds from issuance of common stock from exercise of stock options | 5K |
| Issuance costs related to stock warrant exercises | |
| Issuance costs related to conversion of convertible senior notes | |
| Net cash provided by financing activities | |
| Effect of exchange rate changes on cash and cash equivalents | |
| Net increase in cash and cash equivalents | -10.56M |
| Cash and cash equivalents, beginning of period | 18.64M |
| Cash and cash equivalents, end of period | 8.08M |
| Interest | 24K |
| Principal reduction from conversion of senior convertible notes | |
| Principal reduction from forgiveness of Quest Diagnostics secured line of credit | |
| Issuance of common stock from warrant exercise | |
| Issuance of common stock from conversion of principal and interest for senior convertible notes | |
| Unrealized loss (gain) on investments | |